Hyoscine Butylbromide for Prevention of Bradycardia During Cesarean Section

Assiut University

Status and phase

Completed

Phase 4

Conditions

Bradycardia

Cesarean Section Complications

Spinal Anesthetics Causing Adverse Effects in Therapeutic Use

Treatments

Drug: Hyoscine Butylbromide 20 Mg/mL Solution for Injection Ampoule

Other: Normal saline

Study type

Interventional

Funder types

Other

Identifiers

NCT04069078

hyoscine

Details and patient eligibility

About

The aim of this study is to assess the efficacy of Iv hyoscine butylbromide in preventing Bradycardia during cesarean section under spinal anaesthesia with local anaesthetic and morphine.

Enrollment

173 patients

Sex

Female

Ages

18 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

ASA physical status class I-II.
Age: 18 Years to 40 Years.
Women scheduled for elective Cesarean section under spinal anesthesia.
indications for CS other than fetal or maternal pathology.

Exclusion criteria

Height < 150 or > 180 cm
Body mass index (BMI) >35 kg/m2
Contraindication for central neuraxial block
Refusal to undergo regional anesthesia
Known allergy to any of the study drugs,
Infection at the site of injection,
Coagulopathy,
Indication to general anesthesia
Baseline bradycardia (heart rate < 60/min), or any cardiovascular disease
Patients taking β-adrenergic blockers or any drugs that may alter normal response to study drugs.
Arrhythmia such as atrial fibrillation, supraventricular tachycardia, heart block greater than first degree, left bundle branch block,
Hypertension (systolic blood pressure more than 140 mm Hg or diastolic blood pressure more than 90 mm Hg), unstable angina or cardiomyopathy,
Associated medical problem with pregnancy (as hypertension, diabetes mellitus, hepatic impairment or renal impairment)